Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 40.91% and 11.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction from robust Peripheral Intervention arm and solid international presence. Forex, although, remains a concern.
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.
Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss
by Zacks Equity Research
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.
Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 40.54% and 7.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Merit Medical (MMSI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.
Merit Medical (MMSI) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 25.58% and 3.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Cardinal Health (CAH) Unveils New Logistics Management Tool
by Zacks Equity Research
Cardinal Health's (CAH) company, OptiFreight Logistics, launched TotalVue Analytics to help healthcare supply chain leaders to drive cost savings.
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
by Zacks Equity Research
DENTSPLY (XRAY) acquires Byte to strengthen presence in the lucrative clear aligner space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
by Zacks Equity Research
Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.